Trials / Withdrawn
WithdrawnNCT02084004
Effects of Berberine Hydrochloride and Bifidobacterium in Diabetes Mellitus Prevention and Treatment
Effects of Berberine Hydrochloride and Bifidobacterium in Diabetes Mellitus Prevention and Treatment：an Open-label, Multicenter，Randomized, Prospective，Controlled Study
- Status
- Withdrawn
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Xijing Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to assess the beneficial effects of Bifidobacterium Hydrochloride and Berberine on lowering glucose in patients with type 2 diabetes mellitus and to detect the potential mechanism.
Detailed description
Gut microbiota maybe play an important role in patients with type 2 diabetes mellitus (T2DM). Berberine, which is usually used as an antibiotic drug, has been reported a potential glucose-lowering effect in vitro and in vivo studies. Bifidobacterium, as a familiar probiotics, can modulate gut microbiota and improve glucose and lipid metabolism in animal experiments. Therefore, the aim of this study is to assess the beneficial effects of Bifidobacterium Hydrochloride and Berberine on lowering glucose in patients with T2DM and to detect the potential mechanism.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bifidobacterium viable pharmaceutics | |
| DRUG | Berberine Hydrochloride |
Timeline
- Start date
- 2015-11-01
- Primary completion
- 2018-04-01
- Completion
- 2018-04-01
- First posted
- 2014-03-11
- Last updated
- 2018-11-14
Locations
4 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02084004. Inclusion in this directory is not an endorsement.